Universal Cells creates Universal Donor Stem Cells by editing the genes required for immune recognition. By using our recombinant Adeno-Associated Virus (rAAV) technology, we design and manufacture stem cell-based products that can be used as off-the-shelf cell therapies.
Universal Donor Cells are pluripotent and can differentiate into various cell types that can be used to treat a vast number of diseases. Learn more about the Universal Cells’ pipeline and partnerships.
Tokyo, October 19, 2017 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, “Astellas”) and Universal Cells, Inc. (CEO: Claudia Mitchell, “Universal Cells”) today announced that Astellas Institute for Regenerative Medicine (“AIRM”) and [...]
Universal Cells to utilise CGT Catapult’s induced Pluripotent Stem Cells to create universally accepted cells for research and commercial use London, UK, 5 October 2017 – The Cell and Gene Therapy Catapult (CGT Catapult) today [...]
CAMBRIDGE, MA and SEATTLE, WA, October 3, 2017－BlueRock Therapeutics and Universal Cells Inc. today announced that they have entered into a collaboration and license agreement to create induced pluripotent stem (iPS) cell lines useful for [...]